Traumakine update
Faron Pharmaceuticals Oy ("Faron" or the "Company") Traumakine update - New trial protocol preventing concomitant corticosteroid use with Traumakine - Company notes WHO recommendations on use of steroids in coronavirus patients Company announcement, 06 February 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on Traumakine's clinical continuation following a meeting with the U.S. Food and Drug Administration (FDA) in